Abstract #4359

Perfusion MRI as the predictive/prognostic and Pharmacodynamic Biomarkers in Recurrent Malignant Glioma Treated with Bevacizumab: A Systematic Review and a time-to-event meta-analysis

Kyung Won Kim¹, Sang Hyun Choi¹, Seung Chai Jung¹, Ja Youn Lee², Ho Sung Kim¹, and Seong Ho Park¹

¹Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, ²National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of

The current evidence in the literature shows that the rCBV of DSC-MRI is the most widely used perfusion MRI parameter. The rCBV can be used to predict disease progression and overall survival in patients with recurrent malignant glioma treated with BVZ. Various perfusion MRI parameters from DSC-MRI and DCE-MRI could play a role as pharmacodynamic biomarkers to evaluate the drug’s anti-angiogenic effect on tumor.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.